Theratechnologies got the unanimous endorsement of an FDA panel for tesamorelin, a drug that reduces abdominal fat in HIV patients. The FDA is scheduled to issue an approval decision by July 27.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||